Objectives-To investigate the frequency and potential prognostic or predictive value of HER-2 amplification or overexpression in advanced and recurrent endometrial cancers.
INTRODUCTION
Endometrial cancer is the fourth most common cancer among women in the United States. 1 While early stage endometrial cancer is usually curable with surgery, advanced disease has a poor prognosis. Median survival on recent GOG protocols for advanced or recurrent disease is about a year. 2 A recent randomized phase III study, GOG #177, enrolled patients with measurable stage III, stage IV, or recurrent endometrial carcinoma, and randomly assigned treatment as either doxorubicin and cisplatin (AP) or doxorubicin, cisplatin, and paclitaxel with G-CSF (TAP). The primary results of this trial have been published and showed a superior overall response (57% vs 34%), progression-free survival (median 8.3 vs 5.3 months), and OS (median 15.3 vs 12.3 months) with the three-drug combination. 3 HER-2 is one of the most-studied molecular markers in anticancer therapy. HER-2 (HER-2/ neu, ERBB2) encodes an 185kD transmembrane cell surface receptor glycoprotein with tyrosine kinase activity that belongs to the epidermal growth factor receptor family. HER-2 amplification or overexpression has been reported in 4% to 69% of endometrial carcinomas, and some series note it to be overexpressed more often in tumors of serous histology, which are aggressive cancers with a propensity to metastasize early. 4 The clinical relevance of HER-2 is best established in breast cancer. HER-2 amplification/ overexpression is found in 15-30% of human breast cancers and is an independent prognostic factor for increased likelihood of relapse in early stage disease. 5 It has also been reported to be a predictive marker of resistance to tamoxifen therapy, benefit from doxorubicin-based adjuvant chemotherapy and benefit from trastuzumab (anti-HER-2 monoclonal antibody) in both the adjuvant and metastatic disease setting. [6] [7] [8] A number of clinical trials have also suggested that HER-2 status is predictive for response to taxanes. 9-12 However, not all the evidence is supportive. Van Poznak et al evaluated tumor samples from patients treated on a series of trials using single agent taxanes for metastatic breast cancer, and found no correlation between HER-2 status and response to therapy, although they did observe resistance to therapy in tumors expressing phosphorylated HER-2. 13,14 The objectives of this study were to examine the effects of HER-2 expression and amplification on overall outcomes in women with advanced endometrial carcinoma and explore the possibility of a differential treatment effect for paclitaxel in patients with advanced HER-2 positive endometrial carcinoma.
MATERIALS AND METHODS

Patient Materials
Tumor blocks or cut slides from either primary or recurrent tumor were available for 234 of 263 eligible patients participating in GOG #177. Sufficient sample remained after IHC for FISH analysis in 182 of these 234 cases. Central pathology review documenting cell type and grade was performed.
IHC assay
Immunostaining was performed on 5-μm-thick formalin-fixed, paraffin-embedded specimens using DAKO Herceptest® Kit (supplied by DAKO Corp., Carpenteria, CA). Scoring was performed according to manufacturer recommendations. Zero: undetectable staining or membrane staining in <10% of the tumor cells. 1+: faint and incomplete membrane staining in >10% of the tumor cells; 2+: weak to moderate complete membrane staining in >10% of the tumor cells; 3+: strong complete membrane staining observed in >10% of the tumor cells. HER-2 protein expression was categorized as negative (scores 0 and 1+), or positive (scores 2+ and 3+), consistent with most of the literature in endometrial carcinoma. 15,16
FISH assay
Fluorescence in situ hybridization for detection of HER-2 gene amplification was performed on tissue sections adjacent to those analyzed by IHC using the Vysis, Inc. PathVysion HER-2 DNA Probe Kit (Vysis/Abbot Inc., Des Plaines, IL), which is a hybridization mixture of a HER-2 probe labeled with Spectrum Orange, and a chromosome 17 enumeration probe CEP17, labeled with Spectrum Green. Slides were pretreated using the Vysis/Abbot Inc. Paraffin Pretreatment Kit. In each tumor sample an average of 82 well-defined malignant nuclei were scored. Both the absolute number of HER-2 signals and the ratio of HER-2 signals to CEP17 signals were recorded. Tumors with a HER-2:CEP17 signal ratio < 2 were considered non-amplified; those with a ratio of 2 or greater were considered amplified. The chromosome 17 copy number alteration was estimated using two approaches: 1: calculation of the percentage of cells with given copy number as described previously; 2: calculation of the mean copy number per cell according to Santin et al. 17, 18 In the latter method monosomy was defined as mean CEP17 copies per cell less than 1.5, disomy was defined as mean CEP17/cell of 1.5 to 2.5, and polysomy was defined as mean CEP17/cell of 2.5 or more.
Clinical endpoint
OS was defined as the length of life measured from the date of entry on to the clinical trial. Clinical response was defined as either complete disappearance of all gross disease or at least a 50% reduction in the product of perpendicular diameters of each lesion for a minimum of four weeks. 3
Statistical Analysis
Fisher's Exact test was used to test for independence between the baseline categorical and HER-2 covariates and CEP17 aneusomy (1.5 or fewer copies per cell, 1.5-2.5 copies per cell and greater than 2.5 copies per cell). The Kruskal-Wallis test was used to compare the distributions of the number of HER-2 and CEP17 copies per cell, mean copy number ratio of HER-2 to CEP17, and the proportions of polysomic, monosomic and aneusomic cells between cell type groups. Additionally, the distributions of patient age were compared between HER-2 status groups using the Kruskal-Wallis test. The Kaplan-Meier method was used to estimate and plot the failure time distributions by HER-2 status. Cox proportional hazard models were used to explore the relationship between OS and both HER-2 expression and HER-2 amplification. All models included treatment and the main effect terms for either HER-2 expression or HER-2 amplification. Treatment by HER-2 interaction terms were tested in each proportional hazards model. Hazard ratio estimates are reported with 95% Wald confidence intervals. Logistic regression modeling was used to explore the relationship between clinical response to treatment and both HER-2 expression and amplification. The effect of HER-2 overexpression and amplification on the odds of response was estimated as an odds ratio (OR) adjusted for treatment. Treatment-by-HER-2 interaction terms were also tested. OR estimates are reported with 95% Wald confidence intervals. Except for subgroup analyses, performance status was included in all models as a covariate (0 or 1 vs. 2).
HER-2 expression was analyzed in two different ways. The first grouped 0 and 1+ together versus 2+ and 3+. The second separated out the 2+ from 3+ patients, creating three categories: 0 or 1+, 2+, and 3+. The relationships between survival and clinical response endpoints and HER-2 amplification were also analyzed in two ways: using HER-2 as a binary variable with a cut off ratio ≥2, and using HER-2 as a continuous variable.
All analyses were considered exploratory in nature. Unless otherwise indicated, a level of 0.05 was used to designate statistical significance. All P-values reflect the significance of two-tail tests. No adjustments were made to account for multiple comparisons. Patients who were not evaluated for either assay were excluded from all analyses. Additionally, patients with non-informative FISH results were excluded from statistical analyses involving HER-2 amplification.
In analyses of grade, twelve tumors were included in the "grade 3" category which actually had a grade noted as "not specified". Nine of these were serous or clear cell tumors; some pathologists consider grading of these subtypes inappropriate.
RESULTS
Clinical and tumor characteristics of the overall group of patients, the group on whose tumors IHC staining was performed, and the group available for FISH analysis were similar. FISH was interpretable in 169 of 182 (93%) cases. Thirteen tumors were non-informative due to technical problems related either to poor tissue morphology and tissue conservation or FISHrelated problems.
Tumor cells from 104 of 234 patients (44%) showed positive (2+/3+) cellular membrane HER-2 expression on IHC staining (Table 1A) . Of these, 46 tumors (20%) were strongly HER-2-positive (3+) and 58 tumors (25%) were moderately positive (2+). There was a statistically significant association between HER-2 overexpression with histologic type of tumor; 23 of 38 (61%) serous tumors were IHC-positive versus 81 of 196 (41%; P = 0.03) nonserous tumors (Table 1A) . Ten of 38 (26%) serous tumors were strongly IHC-positive (3+) versus 36 of 196 (18%) other histologic subtypes. There were seven patients whose tumors were of clear cell histology; five overexpressed HER-2 (71%). HER-2 amplification was detected in 21 (12%) of 169 endometrial carcinomas (Table 1B) . Of these, 10 tumors showed high levels of HER-2 amplification (ratio ≥ 5.0). The proportion of HER-2-amplified tumors among serous carcinomas was six of 28 (21%), versus 15 of 141 (11%) among all other histologic subtypes (P = 0.12). HER-2 amplification was observed in three of seven patients with clear cell histology.
No significant relationships were detected between either HER-2 expression or HER-2 amplification and patient race/ethnicity or age, performance status, or disease status at study entry. However, tumor grade was significantly related to HER-2 amplification with 3%, 4%, and 21% of grade 1, 2, and 3 tumors respectively, demonstrating amplified HER-2 (P=0.002) (Table 1B) . This held true even when serous tumors were excluded; grades 1, 2, and 3 nonserous cancers had 3%, 2% and 21% of cases amplified, respectively (P=0.003).
Concordance between FISH and IHC was observed in 101 of 169 (60%) cases where both assays were successfully performed: 13 were positive and 88 were negative by both methods (Table 2) Of the twenty FISH negative cases staining 3+ by IHC only 4 samples showed a gain of HER-2 copy number due to polysomy for chromosome 17. Table 3 shows that serous tumors were more likely both to amplify HER-2/neu and to be polysomic for chromosome 17.
There was no significant effect of HER-2 expression or amplification on survival in the group as a whole ( Figure 2 ) after adjusting for treatment and performance status. For the binary categorization, the estimated ratio of the hazards of death of HER-2 2+, 3+ relative to 0, 1+ on survival in the group as a whole was 1.17 (95% confidence interval (CI) 0.88 to 1.55; P=0.28). Similarly, for the three-way categorization, the estimated effect of HER-2 2+ relative to 0, 1+ was 1.16 (95% CI 0.83 to 1.61; P = 0.40) and the estimated effect of HER-2 3+ relative to 0, 1+ was 1.18 (95% CI 0.82 to 1.70; P=0.36).
For the model using a binary categorization for FISH, the estimate of the death hazard ratio of a HER-2/CEP17 of ratio ≥ 2 relative to < 2 was 0.95 (95% CI 0.59 to 1.55; P=0.84) and for the continuous covariate, it was 1.001 (95% CI 0.94 to 1.06; P=0.97).
Evidence of a qualitative treatment by HER-2 amplification interaction with respect to clinical response did not reach statistical significance (interaction OR: 0.15 P=0.06). The estimate of the effect of TAP was positive within the subgroup with nonamplified tumors (OR for treatment TAP relative to AP: 2.75 (95% CI 1.40 to 5.40) and negative within the subgroup with amplified tumors (OR for treatment TAP relative to AP 0.43 (95% CI 0.17 to 1.09). Evidence of a quantitative treatment by HER-2 expression interaction with respect to clinical response in the opposite direction also did not reach statistical significance (interaction OR: 2.42 P=0.11). The estimated ratio of the odds of response to TAP relative to AP is 1.54 (95% CI 0.76 to 3.14) for tumors staining 0 or 1+ and 3.74 (95% CI 1.63 to 8.58) for tumors staining 2+ or 3+ (Table  4B) . Table 4A provides the crude estimates of response and number of patients within HER-2 and treatment subgroups.
There was also no clear evidence of any treatment -HER-2 interaction with respect to survival ( Table 4B 
DISCUSSION
Our study is unique in that we examined only patients with recurrent or advanced measurable disease, and examined outcomes in the setting of uniform first-line chemotherapy treatment. HER-2 amplification was more common in USC relative to other histologic cell types, (21% versus 11%) and, among nonserous tumors, was more common in grade 3 tumors (21%) than in grade 1 or 2 tumors (3% and 2%). The overall results for levels of HER-2 amplification (12%) and overexpression (44%) and the concordance of the two assays are within the ranges reported by others. 4 20 Some of the variability in the percentage of endometrial cancers demonstrating gene amplification is likely due to the mix of tumors in the various series; those such as the current one, which are composed of patients with advanced or recurrent disease, will contain more patients with high grade and serous tumors, which are more likely to demonstrate HER-2 gene amplification. The variability in HER-2 immunostaining results in the literature is probably related both to a different mix of patients in different series, and the wide variety of antibodies and staining conditions used. It is well-known that anti-HER-2 antibodies have very variable sensitivity in formalin-fixed, paraffin embedded tissue, and that other technical issues are also critical. 21 It is possible that it is technical issues with immunohistochemistry that result in some part of the discordance between immunohistochemistry and FISH results in both our and other series. Our results do not support the possibility that gain of HER-2 copies due to polysomy for chromosome 17 is frequently responsible for protein overexpression. 24 We also saw no evidence of particular biologic significance for the subset of tumors that was both amplified and overexpressed, as was suggested by Morrison et al. 16 Previous studies have varied widely in their conclusions about whether HER-2 is of prognostic value in endometrial cancer. 4,21,22,25-28 Coronado et al found the prognostic value of HER-2 overexpression to be higher in early stages than in advanced stages of disease. 29 This might relate to the higher levels of overexpression found in serous and grade 3 cancers. Serous histology is a poor prognostic indicator in early-stage disease, but in the setting of GOG trials for advanced and recurrent disease it is only a weak prognostic factor (relative hazard ratio for OS 1.2) and does not predict for chemotherapy response. 30 Saffari et al, whose retrospective series of 90 cancers (82% of which were stage I or II) included only three serous tumors, none of which were HER-2 amplified, also noted HER-2 overexpression to be a predictor of poor OS on multivariable analysis, and additionally found that adjuvant chemotherapy or radiotherapy were associated with improved survival only among tumors that overexpressed HER-2. 15 Our study does not suggest any effect of HER-2 amplification or expression on survival in the setting of advanced or recurrent endometrial carcinoma undergoing first-line chemotherapy. It could be hypothesized that any survival difference for women with an aggressive subset of tumors will be less evident in a setting where everyone receives chemotherapy. However, the number of cases with HER-2 amplification in both our series and in the other series in the literature is small, limiting the precision of results.
There was also no clear evidence from the current study to suggest a differential effect of paclitaxel on survival between patients with HER-2 amplified tumors and patients with HER-2 non-amplified tumors. Given the imprecision of the subgroup treatment effect estimates, these results must be viewed with even more caution. Of particular interest is whether overexpression or amplification of HER-2 might predict for response of endometrial cancers to trastuzumab. A complete response to single agent trastuzumab in a patient with USC has been reported. 31 Using entry criteria of IHC 2+ or 3+ staining, GOG #181B found no activity of trastuzumab as a single agent in heavily pretreated women with recurrent or metastatic endometrial cancer. 20 Entry criteria were therefore revised to include only those patients whose tumors were FISH +, but the study was recently closed due to slow enrollment, illustrating the challenges posed in developing tailored treatments to specific biologic subsets in less common tumors. 
